Company profile: Aevi Genomic Medicine
1.1 - Company Overview
Company description
- Provider of research and development in genomic medicine focused on translating genetic discoveries into novel therapies, driven by a commitment to patients with pediatric onset life-altering diseases.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Aevi Genomic Medicine
Azafaros
HQ: The Netherlands
Website
- Description: Provider of oral azasugar-based therapeutic agents targeting rare lysosomal storage disorders, including the investigational small molecule nizubaglustat for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C. Offers the PRONTO natural history study and the RAINBOW clinical study evaluating nizubaglustat, plus an expanded access policy for AZ-3102 limited to clinical trial participation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Azafaros company profile →
Spruce Biosciences
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies for rare endocrine diseases, including tildacerfont, a CRF1 receptor antagonist in late-stage clinical trials for classic congenital adrenal hyperplasia and potentially other conditions with elevated ACTH. Conducts CAHMELIA 203, a double-blind, placebo-controlled, dose-ranging study evaluating tildacerfont's efficacy and safety in adults with CAH.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Spruce Biosciences company profile →
Vtesse Pharma
HQ: United States
Website
- Description: Provider of rare disease drug development for underserved patients, working collaboratively to advance VTS-270, which has shown promise in pre-clinical and clinical studies as a potential treatment for Niemann-Pick Disease; first spin-out of Cydan Development, Inc., an orphan-drug accelerator.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vtesse Pharma company profile →
Clementia Pharmaceuticals
HQ: Canada
Website
- Description: Provider of clinical-stage, disease-modifying treatments for ultra-rare bone disorders and other debilitating diseases with high unmet medical need, including development of its lead product candidate, palovarotene, an oral small molecule.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Clementia Pharmaceuticals company profile →
eTherapeutics
HQ: United Kingdom
Website
- Description: Provider of drug discovery and development solutions using proprietary computational systems to analyze and predict medicine–cell interactions, optimizing efficacy and minimal side effects. Includes HepNet™ computational biology and GalOmic™ RNAi platforms, with candidates ETX-312 (MASH), ETX-407 (dAMD), ETX-148 (haemophilia), and ETX-291 (cardiometabolic).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full eTherapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Aevi Genomic Medicine
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Aevi Genomic Medicine
2.2 - Growth funds investing in similar companies to Aevi Genomic Medicine
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Aevi Genomic Medicine
4.2 - Public trading comparable groups for Aevi Genomic Medicine
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →